MarketInOut Stock Screener Log In | Sign Up

SELLAS Life Sciences Group Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
SELLAS Life Sciences Group Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,016.97 mln
Float200 mln
Earnings Date11/18/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

31 / 100
Underperforming

Debt / Equity

0.01
Debt-free

ROE

-41.86
Deeply negative

ROA

-38.48
Deeply negative

Business Description

SELLAS Life Sciences Group is a New York-based biopharmaceutical company working to bring new cancer treatments to patients. Its two main drug candidates target cancer through different mechanisms ? one by training the immune system to fight tumors, and the other by blocking a protein that helps cancer cells grow. The company works alongside well-known partners, including Merck and Memorial Sloan Kettering Cancer Center, to advance these treatments through clinical trials covering a range of cancer types.

Key Fundamentals

EPS-0.21
ROE-41.86
ROIC-752
ROA-38.48
EBITDA, mln-32.46
EV / EBITDA-65.68
EV / EBIT-65.68

Quote Details

Last 9.68
Change -0.47 (-4.63%)
Open 9.63
Volume 6,091,837
Turnover 58,968,984
Average Volume 6,542,512

Financial Ratios

Leverage Ratio1.06
Current Ratio18.83
Price / Book17.90
Price / Tangible Book18.16
Debt / Equity0.01

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio10.31
Short % of Float26.73

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -16.12% 5 / 100   
1 Month -14.56% 24 / 100   
2 Months -10.7% 31 / 100   
6 Months 96.35% 98 / 100   
1 Year 365% 100 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog